Plexision has been awarded a National Science Foundation (NSF) Phase 1 Small Business Innovation Research Grant.
Personalized Medicine For Better Health
19, Oct 2020
11, Sep 2014
PITTSBURGH, Sept. 11, 2014 /PRNewswire-iReach/ -- Today the FDA announced approval of PleximmuneTM
27, Nov 2013
Prognostic cell-based assay predicts acute cellular rejection in pre- and post-transplant testing...
Chethan Ashokkumar1, Rafia Khan1, Kyle A. Soltys1,Geoffrey Bond1, George V. Mazariegos1,
Brandon W. Higgs1, Rakesh Sindhi1
INSTITUTIONS (ALL): 1. Children's Hospital of Pgh of UPMC, Pittsburgh, PA, United States.
11, Nov 2013
Novel antibody-drug conjugates (ADC), some with dual cellular targets, are revolutionizing the delivery of potentiall
3, Nov 2013
The PleximmuneTM test is the first blood test of its kind to predict whether acute cellular rejection will occur in children with liver or intestine transplantation.
22, Oct 2013
The American Transplant Congress was held between May 18-22 in Seattle this year. The American Transplant Congress is the premier venue for scientific exchange between the various disciplines uniquely involved in solid organ transplantation.
2, Aug 2013
Results from Plexision’s pharma collaboration to be reported at the European Society for Organ Transplantation Congress, Vienna | September 8-11
28, Feb 2013
Plexision performs custom R and D projects aimed at integrating biomarker targets in all phases of drug development, from preclinical to post-marketing.
23, Feb 2013
Traditional tests for immunologic diseases measure disease activity with non-specific injury markers, markers of fully evolved injury, or by measuring the disease agent itself. A need exists to predict whether immunological disease will occur with tests which are highly specific for that disease.
About
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to
- - Assess disease risk for several immunological disorders.
- - Predict the success of a drug for a specific patient.
- - Develop dosing recommendations for new immunological drugs.
Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.
Contact
- +1 (855) 753-9474
- info@plexision.com
- 4424 Penn Ave., #202, Pittsburgh, PA 15224 USA